European Biopharmaceutical Review |
 |
|
|
|
|
 |
| |
|
|
|
|
|
A Conversation About Systemic Sclerosis
Dr Alexandre Akoulitchev and Dr Ewan Hunter, the Chief Scientific Officer and Chief Data Officer of Oxford BioDynamics, respectively, discuss with EBR the R&D and treatment options available for systemic sclerosis.
|
|
|
|
The Importance of Patient Advocacy
Jennifer McGrain at Zambon shares her views with EBR surrounding the vital role patient advocates have in helping patients deal with their conditions, particularly those suffering from rare diseases who may struggle to find vital support.
|
|
|
|
|
|
Novel Approaches to Overcome CRISPR In Vitro Delivery Challenges
Dr Paul Monnier at Cytosurge
Although CRISPR is widely used in research laboratories, many challenges regarding delivery and safety remain to be overcome for both in vivo and in vitro applications.
|
|
|
|
Choosing the Right CRISPR Tools to Generate Your Genetically Modified Mice
James Chon at GenScript
Genetically modified mice are a vital part of life science research, however, the prolonged, financially burdensome process may be changing.
|
|
|
|
How Gene Editing May Pave the Way for Personalised Medicine
Rolf Turk at Integrated DNA Technologies
In the eight years since the seminal paper on CRISPRCas9 gene editing was published, the technology has presented with a huge amount of potential for bringing novel therapies to patients suffering from single gene mutation diseases.
|
|
|
|
The Solution to Complex CRISPR Modifications: Droplet Digital PCR
Dr Karen McAulay, Zara Puckrin, and Dr Robert Annand at REPROCELL
Steps must be taken to ensure the scientific and commercial viability of the CRISPR-Cas9 system if the technology is to reach its full potential.
|
|
|
|
|
|
Treatment Options for Clostridioides Difficile
Shelley McLendon and Kelley Struble at ICON
The increase of hospitalisations, caused by COVID-19, has also seen an uptick in the spread of antimicrobial diseases such as C diff: now an urgent antibiotic resistance threat.
|
|
|
|
The Other – Silent – Pandemic
Philippe Villain-Guillot at Nosopharm
Antibiotic resistance is a severe threat to world health, one that is exacerbated by the pharmaceutical industry’s ageing antibiotic arsenal that has yet to be sufficiently renewed.
|
|
|
|
Another Crisis Is Brewing
Regina Au at BioMarketing Insight USA
The costly and time-consuming models for drug development must change in order for pharma companies to produce new antibiotics and effectively combat antimicrobial resistance.
|
|
|
|
|
|
How Pharma Can Conquer the Next Pandemic
Vladimir Tkachenko at Amaxa Pharma
Months into the pandemic, it’s worth taking a look at what measures have been taken, and what lessons have been learned by the pharma industry, to ensure it will be ready for the next pandemic – whenever it should occur.
|
|
|
|
Fluidity One-W Serum
Accurately characterising the immune response against SARSCoV- 2 is vital in managing the current COVID-19 pandemic; Fluidity One-W Serum could be the solution in the development of reliable antibody tests.
|
|
|
|
Medical Communications Transformed
Shairose Ebrahim at integrated medhealth communication (imc)
COVID-19 has led to the drastic transformation of many professional sectors, including those in the medical community. The medical communications sector has been instrumental in making these transformations as smooth as possible.
|
|
|
|
|
Boston Diary – Day 144
144 days after COVID-19 hit his hometown of Boston, EBR’s industry advisor, Emile Bellot, reflects on all that has changed, and whether the world will ever be the same again. |
|
|
|
|
Changing Perceptions
Aras Azadian of Avicanna
The medicinal benefits of cannabis are quickly becoming undeniable in this new climate. Aras Azadian, CEO of Avicanna, speaks to EBR about the remaining stigma and the potential benefits of cannabinoids.
|
|
|
|
The Numerous Challenges of a Rapidly Developing Sector
Carl Niedbala at Founder Shield
Now, more than ever, the biotech industry faces a significant number of risks, including a lengthy pipeline, the complicated process of gaining FDA approval, and higher healthcare costs.
|
|
|
|
Neoantigens: IP Considerations for an Emerging Class of Cancer Immunotherapy
Fran Salisbury and Ine Vanderleyden at Mewburn Ellis
Previously, cancer treatments took a ‘one-size-fits-all’ approach; however, new personalised clinical technologies are being developed that can incite a patient’s immune system to destroy cancer cells in the body.
|
|
|
|
Mesenchymal Stem Cells: The Next Generation of Pain Treatments
Leo Lee at Regeneus
Pain has always been, and remains, a major burden for patients, stemming from a variety of diseases. Regenerative treatments, such as stem cell treatments using mesenchymal stem cells, may be able to help carry that burden.
|
|
|
|
|
|
.png){kind=small}
.png)
